Literature DB >> 24714398

Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.

Kiichiro Ueta1, Tracy P O'Brien1, Gregory A McCoy1, Kuikwon Kim1, Erin C Healey1, Tiffany D Farmer2, E Patrick Donahue2, Audree B Condren1, Richard L Printz3, Masakazu Shiota4.   

Abstract

A loss of glucose effectiveness to suppress hepatic glucose production as well as increase hepatic glucose uptake and storage as glycogen is associated with a defective increase in glucose phosphorylation catalyzed by glucokinase (GK) in Zucker diabetic fatty (ZDF) rats. We extended these observations by investigating the role of persistent hyperglycemia (glucotoxicity) in the development of impaired hepatic GK activity in ZDF rats. We measured expression and localization of GK and GK regulatory protein (GKRP), translocation of GK, and hepatic glucose flux in response to a gastric mixed meal load (MMT) and hyperglycemic hyperinsulinemic clamp after 1 or 6 wk of treatment with the sodium-glucose transporter 2 inhibitor (canaglifrozin) that was used to correct the persistent hyperglycemia of ZDF rats. Defective augmentation of glucose phosphorylation in response to a rise in plasma glucose in ZDF rats was associated with the coresidency of GKRP with GK in the cytoplasm in the midstage of diabetes, which was followed by a decrease in GK protein levels due to impaired posttranscriptional processing in the late stage of diabetes. Correcting hyperglycemia from the middle diabetic stage normalized the rate of glucose phosphorylation by maintaining GK protein levels, restoring normal nuclear residency of GK and GKRP under basal conditions and normalizing translocation of GK from the nucleus to the cytoplasm, with GKRP remaining in the nucleus in response to a rise in plasma glucose. This improved the liver's metabolic ability to respond to hyperglycemic hyperinsulinemia. Glucotoxicity is responsible for loss of glucose effectiveness and is associated with altered GK regulation in the ZDF rat.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  glucokinase; glucotoxicity; hepatic glucose flux; sodium-glucose cotransporter 2 inhibitor; type 2 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24714398      PMCID: PMC4042096          DOI: 10.1152/ajpendo.00507.2013

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  48 in total

1.  Measurement of glucose homeostasis in vivo: combination of tracers and clamp techniques.

Authors:  Masakazu Shiota
Journal:  Methods Mol Biol       Date:  2012

2.  Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation.

Authors:  D Farrelly; K S Brown; A Tieman; J Ren; S A Lira; D Hagan; R Gregg; K A Mookhtiar; N Hariharan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 3.  Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A Defronzo
Journal:  Endocr Rev       Date:  2011-05-23       Impact factor: 19.871

Review 4.  Glycemic control and complications in type 2 diabetes mellitus.

Authors:  Mark Stolar
Journal:  Am J Med       Date:  2010-03       Impact factor: 4.965

5.  Diabetes in Zucker diabetic fatty rat.

Authors:  Masakazu Shiota; Richard L Printz
Journal:  Methods Mol Biol       Date:  2012

6.  Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats.

Authors:  M Nawano; A Oku; K Ueta; I Umebayashi; T Ishirahara; K Arakawa; A Saito; M Anai; M Kikuchi; T Asano
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-03       Impact factor: 4.310

Review 7.  SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.

Authors:  Raktim Kumar Ghosh; Samhati Mondal Ghosh; Shalini Chawla; Sarfaraz Abdeli Jasdanwala
Journal:  J Clin Pharmacol       Date:  2011-05-04       Impact factor: 3.126

8.  Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase.

Authors:  C Shiota; J Coffey; J Grimsby; J F Grippo; M A Magnuson
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

9.  Defective glycogenesis contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyperinsulinemia in zucker diabetic fatty rats.

Authors:  Tracy P Torres; Yuka Fujimoto; E P Donahue; Richard L Printz; Karen L Houseknecht; Judith L Treadway; Masakazu Shiota
Journal:  Diabetes       Date:  2011-07-19       Impact factor: 9.461

Review 10.  Molecular physiology of mammalian glucokinase.

Authors:  P B Iynedjian
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

View more
  6 in total

1.  Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial.

Authors:  Fumio Sawano; Nozomu Kamei; Mitsue Miyahara; Kyoko Kobuke; Shuhei Nakanishi; Chihiro Nagano; Hideki Nojima; Shusaku Maeda; Hiroshi Watanabe; Rui Kishimoto; Mami Yamashita; Aya Hamaoka; Kana Mukai; Tomoko Tsuboi; Hisayoshi Mochizuki; Reiko Nakashima; Yu Sakashita; Hisaaki Morishita; Tadahiro Kitamura
Journal:  Diabetol Int       Date:  2021-02-11

2.  Role of glucokinase in the subcellular localization of glucokinase regulatory protein.

Authors:  Ling Jin; Tingting Guo; Zhixin Li; Zhen Lei; Hui Li; Yiqing Mao; Xi Wang; Na Zhou; Yizhuang Zhang; Ruobi Hu; Xuehui Zhang; Gang Niu; David M Irwin; Huanran Tan
Journal:  Int J Mol Sci       Date:  2015-04-02       Impact factor: 5.923

3.  Decreased expression of hepatic glucokinase in type 2 diabetes.

Authors:  Rebecca A Haeusler; Stefania Camastra; Brenno Astiarraga; Monica Nannipieri; Marco Anselmino; Ele Ferrannini
Journal:  Mol Metab       Date:  2014-12-18       Impact factor: 7.422

4.  Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle.

Authors:  Tracy P O'Brien; Erin C Jenkins; Shanea K Estes; Antonio V Castaneda; Kiichiro Ueta; Tiffany D Farmer; Allison E Puglisi; Larry L Swift; Richard L Printz; Masakazu Shiota
Journal:  Diabetes       Date:  2017-02-28       Impact factor: 9.461

5.  SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.

Authors:  Takayoshi Suga; Osamu Kikuchi; Masaki Kobayashi; Sho Matsui; Hiromi Yokota-Hashimoto; Eri Wada; Daisuke Kohno; Tsutomu Sasaki; Kazusane Takeuchi; Satoru Kakizaki; Masanobu Yamada; Tadahiro Kitamura
Journal:  Mol Metab       Date:  2018-10-27       Impact factor: 7.422

6.  The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.

Authors:  Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Manuel Campos-Toimil; Tomás García-Caballero; Luis Barral; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; Isabel Moscoso; Ricardo Lage; José Ramón González-Juanatey; Sandra Feijóo-Bandín; Francisca Lago
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.